Skip to main content

Table 3 Complete cytogenetic response at 6, 12 and 18 months

From: The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis

Intervention Probability of response Response odds ratios
(Mean, 95%CrI) (Mean, 95%CrI)
CCyR at 6 months
Imatinib 400 mg daily 40.1% (Reference Category) N/A (Reference Category)
Dasatinib 100 mg daily 55.3% (22.9-86.7%) 2.98 (0.45-9.76)
Nilotinib 300 mg twice daily 60.7% (21.9-86.8%) 3.06 (0.42-9.85)
Nilotinib 400 mg twice daily 56.8% (20.4-85.5%) 2.77 (0.38-8.82)
Imatinib 800 mg daily 53.8% (35.7-71.8%) 1.92 (0.83-3.81)
CCyR at 12 months
Imatinib 400 mg daily 62.4% (Reference Category) N/A (Reference Category)
Dasatinib 100 mg daily 77.1% (67.2-85.3%) 2.16 (1.23-3.5)
Nilotinib 300 mg twice daily 77.7% (64.8-87.7%) 2.41 (1.11-4.29)
Nilotinib 400 mg twice daily 75.3% (61.0-86.1%) 2.06 (0.95-3.73)
Imatinib 800 mg daily 70.1% (62.1-76.9%) 1.45 (0.99-2.01)
CCyR at 18 months
Imatinib 400 mg daily 71.6% (Reference Category) N/A (Reference Category)
Dasatinib 100 mg daily 79.1% (72.0-85.1%) 1.55 (1.02-2.27)
Nilotinib 300 mg twice daily 83.1% (76.7-88.4%) 2.01 (1.31-3.00)
Nilotinib 400 mg twice daily 80.0% (73.0-85.8%) 1.63 (1.07-2.40)
Imatinib 800 mg daily 77.9% (71.9-83.2%) 1.43 (1.01-1.96)